Suggested remit: To appraise the clinical and cost effectiveness of tirzepatide within its marketing authorisation for treating type 2 diabetes.
Status In progress
Technology type Medicine
Decision Selected
Process TA
ID number 3938

Provisional Schedule

Final draft guidance 08 September 2023 - 22 September 2023
Expected publication 11 October 2023

Project Team

Project lead Thomas Feist

Email enquiries


Companies sponsors Eli Lilly & Company
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Diabetes UK
Professional groups Royal College of Physicians
  UK Clinical Pharmacy Association
Comparator companies Boehringer Ingelheim
  Nova Nordisk
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
01 August 2023 Committee meeting: 2
27 June 2023 - 18 July 2023 Draft guidance
06 June 2023 Committee meeting: 1
12 April 2023 The appraisal committee meeting will now take place on Tuesday 6 June 2023. This is to allow the company to address issues raised in the External Assessment Report.
27 January 2023 The appraisal committee meeting is now scheduled to take place on Wednesday 3 May 2023. This is to allow time to work through technical elements relating to the appraisal.
07 June 2022 Invitation to participate
22 March 2022 - 21 April 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 January 2022 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual